Performance of the Lumipulse plasma <i>p</i> ‐tau217 assay to assess eligibility for amyloid‐lowering therapies
The Lumipulse plasma p-tau217 assay exhibited acceptable diagnostic accuracy for the determination of amyloid pathology when compared to either amyloid-PET or CSF p-tau181/Aβ42. This prospective study confirms the utility a two-cutpoint approach for interpreting plasma p-tau217 for the assessment of amyloid pathology eligibility for amyloid-lowering therapies in a heterogenous clinical cohort.
Authors
- Derek Richard Johnson (ORCID: https://orcid.org/0000-0002-4217-5517)
- Jonathan Graff‐Radford
- Brian J. Burkett (ORCID: https://orcid.org/0000-0002-0457-5712)
- Susan Ashrafzadeh‐Kian (ORCID: https://orcid.org/0000-0003-2991-129X)
- Alicia Algeciras‐Schimnich (ORCID: https://orcid.org/0000-0002-4455-6217)
- Stuart J. McCarter (ORCID: https://orcid.org/0000-0001-8158-8835)
- Joshua A. Bornhorst (ORCID: https://orcid.org/0009-0003-9297-3271)
- Daniel J. Figdore (ORCID: https://orcid.org/0000-0002-4776-3203)
- Petrice M Cogswell
- Ronald Petersen
- Vijay K. Ramanan
Institutions
- Mayo Clinic in Arizona (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_097514
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00